Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology.

Debra J Tompson Mark Whitaker Rennan Pan Geoffrey S Johnson Teresa Fuller Vanessa Zann Litza McKenzie Kathy Abbott-Banner Simon J Hawkins Marcy Powell

Published in: Pharmaceutical research (2022)

The DiffCORE technology overcame the food effect vulnerability observed with the matrix monolithic formulation. The MR-16 h formulation was selected for further clinical development as a QD dosing regimen (NCT03649412 September 26, 2018).

Keyphrases

drug delivery
climate change
signaling pathway
magnetic resonance
computed tomography
pi k akt
ionic liquid
mass spectrometry